There is little more complicated than drug pricing in Medicaid, with a variety of federal and state requirements. An Office of Inspector General report examines whether states are taking full advantage of provisions in the reform law designed to aid in ensuring that Medicaid programs get the best possible drug prices. (OIG Report) The issue takes on heightened importance given the Medicaid expansion taking place in many states under the reform law. Historically, the federal government has calculated a federal upper limit for Medicaid drug reimbursement for drugs with multiple sources, but the states have also had Maximum Allowable Cost programs, which usually had lower prices than the federal upper limit. However, the reform law tasked HHS with resetting the method for calculating the federal upper limit, relating it more to average manufacturer price. The previous methods often resulted in FULs that were well above market prices. Looking at the 45 states with MAC programs, OIG found that most based the MAC on pharmacy acquisition costs, which were generally lower than the pre-reform law FULs, on average the FUL was almost two times greater than the corresponding MAC for a drug. However, the new draft FULs are now often lower than the MAC amounts in the states, by an average of 22%, so OIG reasonably concludes that states should reconsider use of the FULs, which could result in additional savings of billions of dollars. One difficulty, however , is that only about half the drugs on the typical state’s MAC list have a FUL, so CMS may need to expand the range of drugs for which it calculates that metric.
OIG on Medicaid Drug Pricing
By Kevin RocheOctober 16, 2013Commentary
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Another example of over-priced companies trying to find some way to survive in the post-epidemic financial world. Transcarent, which does something, somehow to “access high quality, affordable care” is buying...
March 6, 2023
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace
March 21, 2023
Minnesota’s New Energy Insanity, Part 7
Minnesota is a particularly poor place to rely on solar power, but other states aren't…
March 21, 2023
A Quick SVB Follow-up
As I suspected, the SVB saga is primarily one of regulatory malfeasance, coupled with political…
March 19, 2023
Tom Frieden Speaks in the WSJ
A public health expert writes an article for the WSJ which amply demonstrates why Americans…